SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
DNDN - Dendreon Corp.
An SI Board Since June 2000
Posts SubjectMarks Bans Symbol
751 79 0 DNDN
Emcee:  brk Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
251I've wondered about this too. I didn't attend the investor/analysts conftktrimbath-11/19/2004
250US:DNDN : Downgraded from Buy to Sell $6 by Brean Murray anyone know why? looks The O-11/19/2004
249I'm new to DNDN. I've only recently stumbled onto it and started lookinMarty R-11/14/2004
248Anyone still here?Paul Lee-11/9/2004
247Dendreon Corporation Reports Third Quarter 2004 Financial Results November 09, 2The O-11/9/2004
246DNDN is now beginning to move like it should. I am not if it has anything to doRichard Chowning-11/8/2004
245"I guess it may depend, in part, on the extent to which narrow minded rule-gcrispin-10/31/2004
244<i>If we had the same lack of efficacy in gleason 8 and over, how could heClarksterh-10/31/2004
243This board seems a bit quieter with a higher percentage of thoughtful posts, ratmouton29-10/31/2004
242Mouton - Fancy meeting you over here on these uncluttered boards. Some commentsClarksterh-10/31/2004
241I have not had the chance to review the Vidaza data, but until we see the detailmouton29-10/31/2004
240<i>I also thing that the FDA's approval of Vidaza by Pharmion for MDS Clarksterh-10/31/2004
239I also thing that the FDA's approval of Vidaza by Pharmion for MDS is anothegcrispin-10/31/2004
238Tom - <i>It was a cut-off point chosen by Dendreon (in consultation with tClarksterh-10/30/2004
237Thanks, the slide presentation is very useful in understanding the history of Gltom pope-10/30/2004
236<i>I believe that most immunologists would LOVE to see the >7 group, whClarksterh-10/30/2004
235Pretty cool, doing that. Thanks! I believe that most immunologists would LOVE scaram(o)uche-10/30/2004
234Tom - <i>Is Gleason 7 the cut-off point between moderate disease and diseaClarksterh-10/30/2004
233Please excuse my ignorance. Is Gleason 7 the cut-off point between moderate disetom pope-10/30/2004
232Notes from the 10/28 Conf Call (post the announcement of Provenge Stat Sig in ITClarksterh-10/30/2004
231www.fdaadvisorycommittee.com/FDC/AdvisoryCommittee/Committees/Oncologic+Drugs/07gcrispin-10/29/2004
230I am not qualified to answer your excellent question so will only comment on youtktrimbath-10/29/2004
229How likely is 'Accelerated' or 'Conditional' Approval based on 9Clarksterh-10/29/2004
228Off Topic - but FYI <<<<<<<<<<<<<<&lJohn McCarthy-9/12/2004
227New Research Report on DNDN biotechstocksignals.comTom Ronk-7/29/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News